このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Surgalign Holdings マネジメント

マネジメント基準チェック /34

Surgalign Holdings'の CEO はTerry Richで、 Jul2020年に任命され、の在任期間は 3.25年です。の年間総報酬は$ 1.21Mで、 45.5%給与と54.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.3%を直接所有しており、その価値は$ 2.15K 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と4.9年です。

主要情報

Terry Rich

最高経営責任者

US$1.2m

報酬総額

CEO給与比率	45.5%
CEO在任期間	3.3yrs
CEOの所有権	1.3%
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

CEO報酬分析

Surgalign Holdings の収益と比較して、Terry Rich の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$1m	US$550k	-US$55m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$66m
Dec 31 2021	US$2m	US$544k	-US$81m
Sep 30 2021	n/a	n/a	-US$152m
Jun 30 2021	n/a	n/a	-US$171m
Mar 31 2021	n/a	n/a	-US$185m
Dec 31 2020	US$2m	US$467k	-US$194m

報酬と市場: Terryの総報酬 ($USD 1.21M ) は、 US市場 ($USD 667.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Terryの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Terry Rich (55 yo)

3.3yrs

在職期間

US$1,209,086

報酬

Mr. Terry M. Rich has been President, Chief Executive Officer and Director of Surgalign Holdings, Inc. since July 2020. He joined Surgalign in November 2019. He was President of Global Spine at Surgalign H...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Terry Rich	President	3.3yrs	US$1.21m	1.3% $ 2.2k
David Lyle	Chief Financial Officer	1.6yrs	US$1.04m	0.47% $ 775.3
Christopher Thunander	VP & Chief Accounting Officer	2.1yrs	US$458.76k	0.18% $ 290.2
Paolo Amoruso	Chief Legal Officer	1.2yrs	データなし	0.12% $ 194.6
Suzanne Zoumaras	Chief People Officer	1.8yrs	データなし	データなし
Enrico Sangiorgio	Executive Vice President of International	3.3yrs	US$573.81k	0.13% $ 217.4
Marc MacKey	Executive Vice President of Digital Surgery	2.5yrs	データなし	0.29% $ 478.0
G. Cornwall	Executive Vice President of Research and Clinical Affairs	no data	データなし	データなし

2.1yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: SRGA.Qの経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Terry Rich	President	3.3yrs	US$1.21m	1.3% $ 2.2k
Paul Thomas	Independent Director	7.3yrs	US$142.50k	0.31% $ 515.0
Sheryl Conley	Independent Chair of the Board	2.4yrs	US$189.47k	0.021% $ 34.7
Mark Stolper	Independent Director	6.6yrs	US$157.50k	0.31% $ 519.6
Nicholas Valeriani	Independent Director	7.3yrs	US$150.00k	0.34% $ 554.6
Elizabeth LaPuma	Independent Director	less than a year	データなし	データなし
Thomas McEachin	Independent Director	7.8yrs	US$150.00k	0.32% $ 533.0
Jill Frizzley	Independent Director	less than a year	データなし	データなし

4.9yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: SRGA.Qの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

Surgalign Holdings マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Chief Financial Officer recently bought US$100k worth of stock

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

President recently bought US$1.0m worth of stock

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System

Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego.

Independent Director has left the company

VP, Chief Accounting Officer & Corporate Controller has left the company

Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019)

Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020

Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders

Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares?

Price target lowered to US$5.00

Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021

マネジメント基準チェック /34